OncoDEEP is a genomic test that helps the oncologist in making therapeutic decisions. The complete molecular characterization of the tumor through the use of the most innovative technologies (NGS, IHQ, among others) together with the analysis of the latest scientific publications, allows us to generate a complete and detailed clinical report with the biomarkers detected and the medications associated with them.
OncoDEEP is the most cost-effective test on the market for molecular characterization of the tumor, which focuses on diagnostic biomarkers specific to the type of cancer. This integrated study combines the study of DNA / RNA with protein analysis to provide valuable information in therapeutic decision making.
The results obtained, both from ultrasequencing and molecular tests, are integrated and interpreted in a complete and detailed clinical report.
Immunohistochemistry analysis is performed according to the type of cancer associated with targeted therapies, chemotherapies, immunotherapies and others.
OncoDEEP has the CE IVD markings and is carried out in an ISO 15189 accredited laboratory.
From the paraffin block tumor sample, more than 70 key genes are sequenced, and immunohistochemical analysis is performed according to the type of cancer associated with targeted therapies, chemotherapies, immunotherapies and others.
In addition to this, an integrated therapeutic report is generated that contains:
The delivery time of the results is 10 business days
OncoDEEP is indicated in adult patients with solid tumors in which: